Myeloma and Amyloid Oncologist, Asst Professor of Medicine@hackensackUMC. Local guide NYC restaurants. Ravenclaw. Tweets are my own
Hackensack, NJ
Joined August 2009
- Tweets1.4K
- Following307
- Followers375
- Likes3.5K
Harsh Parmar MD retweeted
New Research: Primum non nocere: a critical analysis of early intervention clinical trials in smoldering multiple myeloma frontiersin.org/articles/10.… #FrontiersIn #Oncology
Harsh Parmar MD retweeted
PR after induction - "Go on" to ASCT OR "Hold on" for VGPR and then do ASCT. A dilemma which many of us face in practice. Our analysis from my previous workplace which answers this important question @ishbtish @IndMyAcGp @DrPMPGI @UdayYanamandra @IsbmtU
Harsh Parmar MD retweeted
I like this approach. Depositing light chains is toxic, and the treatment of AL should be considered a quasi-emergency! Almost like renal failure in MM.
#everydaymatters
Harsh Parmar MD retweeted
Important clinical pearl from @Ron_Witteles! In cardiac AL, I check FLCs q-weekly in the first couple of months, and switch treatment if I sense plateau. “Every day matters” for the component of toxic cardiomyopathy from circulating FLCs.
Congrats to the authors, but 2 critical points: 1) There’s no role for PYP scan in setting of + monoclonal protein. 2) “Promptly diagnosing” does not mean 1-2 months from time of suspicion. When #AL #amyloidosis is in the differential, it’s a near-emergency — every day matters.
Harsh Parmar MD retweeted
Went to pick up a prescription at the pharmacy and with my prescription card it was $467…. Cash price $63.40. Our healthcare and insurance system, and the Pharmacy benefit managers have created the biggest fraud machine I’ve ever seen.
Harsh Parmar MD retweeted
Google just announced a breakthrough in quantum computing.
It's called "Willow" - and it's making waves in the tech world.
But buried in their announcement was something fascinating:
A discovery that could reshape our understanding of computing itself...
Harsh Parmar MD retweeted
CONGRESS | #ASH24 | Susan Bal @SusanBal9 @UABNews shares extended FU data from the Phase I study of arlo-cel (BMS-986393) in heavily pretreated RRMM. ORR 87%, CR 53%, 150x10^6 CAR T cells ORR 91%, median DoR 18-mo, median PFS 18.3-mo, 12-mo OS 90%.
Follow our live feed for more updates: loom.ly/o2oK2qI
#mmsm #myeloma #MedicalCongress
Harsh Parmar MD retweeted
Most importantly: MRI accounts for a significant number of myeloma-defining events (MDE) and proofs to be a valuable tool.
Harsh Parmar MD retweeted
#Myeloma Paper of the Day: #MGUS risk stratification models can be applied longitudinally to repeatedly determine & improve individual risk of progression, w/ patients who get upstaged to a high-risk category having increased chance of progression: pubmed.ncbi.nlm.nih.gov/3919…. #mmsm
Harsh Parmar MD retweeted
HISTORY IN THE MAKING!!! 🇺🇸🔥🙌
For the first time ever, #TeamUSA have qualified for the Super 8 stage of the @ICC @T20WorldCup! 🤩✨
Congratulations, #TeamUSA! 🙌❤️
Harsh Parmar MD retweeted
Audience cheers for Dr. Shaji Kumar, my friend and colleague @MayoClinic — we announced that he will be receiving the Robert A. Kyle Lifetime Achievement Award this evening at the IIMWG summit in Madrid.
Congrats @myelomaMD
@MayoMyeloma
Harsh Parmar MD retweeted
We will be publishing long-term follow up of various total therapies. We presented last year @ASCO on sum of the long term results
ascopubs.org/doi/10.1200/JCO…
Approximately one out of three patients (standard risk) are cured using such approach
20-yr OS is ~25% in TT II 🌟
Harsh Parmar MD retweeted
These numbers are just staggering !!!!
How did we let this Healthcare industrial machine get so much out of hand
Average man suffering while C suites buying more planes/yachts
Sad state of affairs
Harsh Parmar MD retweeted
#Myeloma Paper of the Day: Minimal residual disease status in multiple myeloma 1 year after autologous hematopoietic cell transplantation and lenalidomide maintenance are associated with long-term overall survival: pubmed.ncbi.nlm.nih.gov/3870….
Harsh Parmar MD retweeted
The problem with the analysis you describe is that mrd measured at 1 year after the transplant decision made. 2/3 of mrd neg patients were in the transplant arm. Don’t get confused by the data. Transplant offers huge benefit
Agreed with @GvHD_Meade - to me, the most fascinating part of DETERMINATION was that patients who achieved MRD negativity with just VRd had no real benefit to ASCT.
Now that we have even better quads, MRD-guided studies like MASTER-2 (cc @End_myeloma) will show us the future!
Harsh Parmar MD retweeted
What Are the Benefits of Myeloma Consults and Second Opinions? powerfulpatients.org/?p=6012…
Harsh Parmar MD retweeted
100%. It’s always fascinated me that the myeloma field is all about intensifying therapy to the utmost - with the *sole* exception of autoHCT, which is the only case where de-escalation seems to be a priority. Yet autoHCT is the cheapest and (arguably) most effective tx we have.
Harsh Parmar MD retweeted
Patients with Waldenström macroglobulinemia and mutations in CXCR4 or TP53 had more favorable outcomes when treated with zanubrutinib vs ibrutinib doi.org/10.1182/bloodadvance…
